SLC7A5 and neoplasm: Moreover, in in vivo assays, we found that knocking-out Slc7a5 reduced tumor growth (Supplementary Fig. 7H, I); while Slc7a5/Sting double-KO cells formed bigger but not statistically significant tumors than those formed by wild-type cells (Fig. 7H and Supplementary Fig. 7J); in line with this, SLC7A5 inhibitor BCH also furtherly reduced tumor growth and increased intratumoral IFN-β under cisplatin or diABZI treatment (Fig. 7I, J and Supplementary Fig. 7K, L).